In a multinational study involving 291 patients with TP53 mutated AML, the combination of azacitidine/decitabine or low-dose cytarabine with venetoclax demonstrated the highest success rate in achieving complete remission (CR) [39]. The gene discussed is TP53; the disease is acute myeloid leukemia.